P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY

Registos relacionados

• Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
  Por: Junichiro Yuda, et al.
  Publicado em: (2023-02-01)
• P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY
  Por: Timothy Hughes, et al.
  Publicado em: (2023-08-01)
• PB1902: ASC4OPT TRIAL IN PROGRESS: A PHASE 3B OPEN-LABEL OPTIMIZATION STUDY OF ORAL ASCIMINIB IN CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE PREVIOUSLY TREATED WITH 2 OR MORE TYROSINE KINASE INHIBITORS
  Por: M. Breccia, et al.
  Publicado em: (2022-06-01)
• S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.
  Por: Thomas Ernst, et al.
  Publicado em: (2023-08-01)
• PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
  Por: Andreas Hochhaus, et al.
  Publicado em: (2023-08-01)